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Abstract 
Background: Mitochondrion is a small organelle inside the eukaryotic cells. It has its own genome (mtDNA) and 
encodes for proteins that are critical for energy production and cellular metabolism. Mitochondrial dysfunctions have 
been implicated in cancer progression and may be related to poor prognosis in cancer patients. In this study we 
hypothesized that genetic variations in mtDNA are associated with clinical outcome in colorectal cancer patients.
Methods: We tested the associations of six mtDNA polymorphisms [MitoT479C, MitoT491C, MitoT10035C, 
MitoA13781G, 10398 (A/G), and 16189 (T/C)] and the mtDNA copy number change with overall survival (OS) and 
disease-free survival (DFS) times. Two mtDNA polymorphisms were genotyped using the TaqMan® SNP genotyp-
ing technique and the genotypes for the remaining four mtDNA polymorphisms were obtained by the Illumina® 
HumanOmni1-Quad genome wide SNP genotyping platform in 536 patients. The mtDNA copy number change (in 
tumor tissues with respect to non-tumor tissues) was estimated using the quantitative real time polymerase chain 
reaction for 274 patients. Associations of these mtDNA variations with OS and DFS were tested using the Cox regres-
sion method.
Results: In both univariate and multivariable analyses, none of the six mtDNA polymorphisms were associated with 
OS or DFS. 39.6 and 60.4% of the patients had increased and decreased mtDNA copy number in their tumor tissues 
when compared to their non-tumor rectum or colon tissues, respectively. However, in contrast to previous findings, 
the change in the mtDNA copy number was associated with neither OS nor DFS in our patient cohort.
Conclusions: Our results suggest that the mitochondrial genetic markers investigated in this study are not associ-
ated with outcome in colorectal cancer.
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Background
The uncontrolled proliferation of cells in colon or rectum 
is referred to as colorectal cancer. The western world has 
increased risk of developing this disease, which may be 
attributed to the lifestyle and dietary factors [1]. Accord-
ing to Global Cancer Statistics, worldwide colorectal 
cancer ranks as the fourth leading cause of cancer-mor-
tality [2].
Mitochondrion is a small organelle in eukaryotic cells 
that exists in several copies. Mitochondria have impor-
tant cellular functions such as energy production in 
the form of ATP through oxidative phosphorylation 
(OXPHOS) pathway, creation of reactive oxygen spe-
cies, and initiation of apoptosis [3]. Mitochondrion has 
its own genome (mitochondrial DNA; mtDNA), which is 
a circular and double stranded DNA molecule approxi-
mately 16.5 kilo bases in length [4]. MtDNA has 37 genes 
out of which 22 code for tRNAs, two code for rRNAs, 
Open Access
*Correspondence:  savas@mun.ca 
1 Discipline of Genetics, Faculty of Medicine, Memorial University 
of Newfoundland, 300 Prince Philip Drive, HSC, Room H4333, St. John’s, 
NL A1B 3V6, Canada
Full list of author information is available at the end of the article
Page 2 of 10Haja Mohideen et al. BMC Res Notes  (2015) 8:272 
and 13 genes code for the respiratory chain proteins of 
the OXPHOS pathway. Genetic alterations in mtDNA 
such as point mutations, deletions and insertions are 
known to cause a metabolic change from OXPHOS to 
glycolysis pathway, which may facilitate cancer progres-
sion and resistance to chemotherapeutic drugs [5]. Since 
mitochondrial dysfunctions may modify cancer progres-
sion, genetic variations in mtDNA may have a prognostic 
role in cancer.
The main objective of this study was to analyze the 
genetic variations in mtDNA for their prognostic asso-
ciations in colorectal cancer. For this purpose, we analyzed 
six single nucleotide polymorphisms (SNPs) in blood-
extracted DNA and the mtDNA copy number change in 
tumor tissue with respect to matching non-tumor tissue 
as mitochondrial genetic markers. Among these six poly-
morphisms, the 10398 (A/G) and 16189 (T/C) polymor-
phisms were selected based on their potential biological 
consequences. The 10398 (A/G) polymorphism is a non-
synonymous substitution located in the mitochondrial ND-
3 (NADH dehydrogenase 3) gene and has been shown to 
promote metastasis, resistance to apoptosis, and increased 
production of reactive oxygen species [6]. The 16189 (T/C) 
polymorphism, on the other hand, is located in the D-loop 
region of mtDNA, results in a heteroplasmic length varia-
tion, and has been hypothesized to affect the mtDNA rep-
lication and its cellular copy number [7, 8]. Four additional 
mtDNA polymorphisms were included in this study based 
on the availability of their genotype information obtained 
through a genome-wide SNP genotyping method. Of these, 
MitoT491C and MitoT479C polymorphisms are located in 
the mitochondrial D-loop region, the MitoA13781G poly-
morphism is located in the mitochondrial ND-5 (NADH 
dehydrogenase 5) gene, and the MitoT10035 polymor-
phism is located in a tRNA gene that is specific for glycine 
codon. Biological consequences of these four mtDNA poly-
morphisms, if ever, are currently not known. In the present 
study, associations of these six polymorphisms with out-
come were investigated in 536 colorectal cancer patients.
Changes in cellular copy number of mtDNA (either an 
increase or decrease when compared to other tissues) are 
observed in tumors, including colorectal cancer tumors 
[9–13]. This change is a surrogate marker for alterations 
in the number of mitochondria and thus its altered func-
tion. In this study in addition to the polymorphisms, 
association of the change in the mitochondrial DNA 
copy number in tumor tissue compared to matching non-
tumor tissue of 274 colorectal cancer patients with out-
come was also investigated.
Methods
Study design
This is a single center and retrospective study.
Study cohorts
Genotyping of the six mtDNA polymorphisms and the 
mtDNA copy number analysis were performed on sub-
sets of a colorectal cancer patient cohort recruited to the 
Newfoundland Colorectal Cancer Registry (NFCCR). The 
NFCCR cohort is a population-based and predominantly 
Caucasian cohort, which was described in detail previ-
ously [14, 15]. Briefly, patients in the NFCCR cohort were 
recruited between January 1999 and December 2003. 
Written consent was obtained from the patients or their 
family members. Patient blood samples were collected and 
used to extract the genomic DNA samples. Demographic, 
clinical and pathological characteristics of patients were 
collected from questionnaires, medical, pathological and 
other clinical records. Outcome status and dates of recur-
rence, metastasis or death were obtained from the clinical 
and hospital records, the Newfoundland Cancer Treat-
ment and Research Foundation database, and by patient/
family contact until April 2010 [16]. Tumor molecular 
characteristics, such as the microsatellite instability (MSI) 
and BRAF1-Val600Glu mutation status were determined 
previously using the tumor-extracted DNA [14]. The 
familial risk assessment was also performed previously as 
described by Green et al. [15].
NFCCR has 736 stage I–IV patients with collected 
prognostic data. For this study, the DNA samples 
(extracted from blood) of 536 of the patients were avail-
able; these patients were genotyped six mtDNA poly-
morphisms. In addition, out of 736 patients, 276 patients 
were investigated for the mtDNA copy number change 
based on the availability of their DNA samples extracted 
from both the tumor and non-tumor colon or rectum 
tissue; 210 of these patients were also investigated in 
the genotyping analysis. Baseline characteristics and the 
other relevant follow-up information of these two patient 
cohorts are summarized in Table 1.
Prior ethics approval was obtained from the Human 
Research Ethics Board (HREB) of Memorial University to 
perform this study.
SNP genotyping methods
Out of the six SNPs genotyped, two SNPs [16189 (T/C; 
rs55749223) and 10398 (A/G; rs2853826)] were geno-
typed using the TaqMan® SNP genotyping technique. 
The primers and probes for the 16189 (T/C) polymor-
phism (Additional file 1: Table S1) were custom designed 
using the assay design tool of Applied Biosystem (https://
www5.appliedbiosystems.com/tools/cadt/) and were 
purchased from the Applied Biosystems (USA). The 
primer and probe sequences for the 10398 (A/G) poly-
morphism were obtained from a published report [17] 
and were manufactured by the Integrated DNA Technol-
ogies (USA) and Applied Biosystems (USA), respectively.
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Table 1 Baseline characteristics of patients included in the qPCR and the SNP genotyped cohorts
Variables qPCR cohort Polymorphism cohort
n (%) n (%)
Sex
 Female 116 (42.03) 208 (38.81)
 Male 160 (57.97) 328 (61.19)
Location
 Colon 183 (66.3) 355 (66.23)
 Rectum 93 (33.7) 181 (33.77)
Histology
 Non-mucinous 243 (88.04) 475 (88.62)
 Mucinous 33 (11.96) 61 (11.38)
Stage
 I 31 (11.23) 98 (18.28)
 II 94 (34.06) 207 (39.62)
 III 101 (36.6) 178 (33.21)
 IV 50 (18.11) 53 (9.89)
Grade
 Well/moderately differentiated 243 (88.04) 493 (91.98)
 Poorly differentiated/undifferentiated 32 (11.6) 39 (7.28)
 Unknown 1 (0.36) 4 (0.75)
Vascular invasion
 − 139 (50.36) 326 (60.82)
 + 111 (40.22) 171 (31.9)
 Unknown 26 (9.42) 39 (7.28)
Lymphatic invasion
 − 137 (49.64) 315 (58.77)
 + 113 (40.94) 179 (33.4)
 Unknown 26 (9.42) 42 (7.84)
Familial risk
 Low 142 (51.45) 256 (47.76)
 High/intermediate 133 (48.19) 280 (52.24)
 Unknown 1 (0.36)
MSI status
 MSI-L/MSS 248 (89.86) 456 (85.07)
 MSI-H 26 (9.42) 58 (10.82)
 Unknown 2 (0.72) 22 (4.1)
BRAF1 Val600Glu mutation
 − 219 (79.35) 436 (81.34)
 + 35 (12.68) 49 (9.14)
 Unknown 22 (7.97) 51 (9.51)
OS status
 Alive 141 (51.09) 353 (65.86)
 Dead 134 (48.55) 182 (33.96)
 Unknown 1 (0.36) 1 (0.19)
Median OS follow-up 6.2 years (range 0.036–10.88) 6.3 years (range 0.38–10.88)
DFS status
 Recurrence/metastasis/death (−) 126 (45.65) 322 (60.07)
 Recurrence/metastasis/death (+) 149 (53.99) 213 (39.74)
 Unknown 1 (0.36) 1 (0.19)
Median DFS follow-up 5.1 years (range 0.036–10.88) 5.98 years (range 0.22–10.88)
Median age 62.4 years (range 31.75–74.94) 61.3 years (range 20.7–74.98)
(+) presence, (−) absence, DFS disease free survival, MSI-H microsatellite instability-high, MSI-L microsatellite instability-low, MSS microsatellite stable, n number of 
patients, OS overall survival, qPCR quantitative PCR.
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For the genotyping experiments, we used 5 µl of PCR 
Master Mix (2X, Applied Biosystems, USA), 0.25  µl of 
20X TaqMan® Assay Mix, 3.75 µl of sterile water and 1 µl 
of DNA solution (4 ng/µl). The thermocycling conditions 
were as follow: Activation of AmpErase® UNG at 50°C 
for 2  min, activation of AmpliTaq Gold polymerase at 
95°C for 10 min, and 34 cycles of denaturation of DNA at 
95°C for 15 s followed by primer annealing and extension 
at 60°C for 1 min, as recommended by the Applied Bio-
systems (USA). The experiments were run on a 7900HT 
Real Time Fast PCR system (Applied Biosystems, USA) 
and the results were analyzed using the Sequence Detec-
tion Software (SDS). The SDS genotype output data were 
also manually inspected by one of us (SS) to finalize the 
genotype data. For 16189 (T/C) and 10398 (A/G), 6.5 and 
13.4% of the patient DNAs were genotyped twice, respec-
tively; in all cases the genotypes obtained were identical.
The genotype data for the remaining four mtDNA 
polymorphisms (MitoT479C, rs41442247; MitoT491C, 
rs28625645; MitoT10035C, rs41347846; MitoA13781G, 
rs41358152) were obtained using a genome wide SNP 
genotyping technique (Illumina Human Omni1-Quad 
genomewide SNP genotyping platform) as part of another 
project of our team. These genotyping reactions were 
performed at an outsourced genotyping facility (Centril-
lion Genomics Services, CA, USA). Initially, genotypes 
for 25 mtDNA SNPs were available in the patient cohort. 
We found that seven of these SNPs were mono-allelic, 
some SNP-flanking sequences had a significant sequence 
homology with nuclear DNA sequences (thus it was 
not clear whether these genotypes were from mtDNA; 
n = 7), and seven SNPs had very low MAFs (<4%); these 
SNPs therefore were excluded from further analysis. As a 
result, the remaining four SNPs were included in the sta-
tistical analysis of this project. There were no duplicate 
samples genotyped using the Illumina® HumanOmni-1 
Quad SNP genotyping method; thus we were not able to 
assess the concordance rate for genotypes obtained for 
these four SNPs. To our best knowledge and based on 
the dbSNP database [18, 19], the nucleotide positions of 
these SNPs are annotated based on the Cambridge Refer-
ence Sequence (NC_001807.4), whereas the positions of 
the TaqMan® genotyped polymorphisms are based on the 
revised Cambridge Reference Sequence (NC_012920.1). 
Throughout the manuscript we kept these positions 
as they are, but for the interested reader the nucleo-
tide positions of the 16189 (T/C) and the 10398 (A/G) 
polymorphisms in the Cambridge Reference Sequence 
(NC_001807.4) are 16190 and 10399, respectively.
Genotype frequencies together with the successful gen-
otyping rates for the six mtDNA polymorphisms inves-
tigated in this study are shown in Additional file 1: Table 
S1.
Quantitative polymerase chain reaction (qPCR) 
for estimation of the mtDNA copy number ratio
The relative mtDNA copy number was estimated using 
a duplex quantitative polymerase chain reaction (qPCR). 
For qPCR reactions, the primer and probe sequences 
were obtained from a previously published literature 
report [20] and the primers and probes were manufac-
tured by the Integrated DNA Technologies (USA) and 
Applied Biosystems (USA), respectively. In this duplex 
reaction, both a fragment of a nuclear gene (FASLG; 
surrogate for the nuclear DNA quantity) and a frag-
ment of a mitochondrial gene (ND-2 gene; surrogate 
for the mtDNA quantity) were amplified in the same 
reaction-well for each DNA sample using the 96-well 
fast PCR plates (Applied Biosystems, USA). The FASLG 
gene amplification data was used to normalize the ND-2 
gene amplification in each reaction to calculate the rela-
tive amplification of the mitochondrial DNA. For each 
patient, two separate qPCR reactions (one for the tumor 
extracted DNA and the other for the non-tumor tissue 
extracted DNA) were performed in triplicates. These 
two DNA samples for each patient were amplified in the 
same reaction plate using the same master reaction mix 
to minimize the inter-assay variability.
For qPCR analysis we used 5 µl PCR Master Mix (2X, 
Applied Biosystems, USA), 0.25  µl 20X TaqMan® Assay 
Mix, 3.25 µl of sterile water and 1.5 µl of DNA solution 
(4  ng/µl). A series of optimization reactions were per-
formed to identify the optimum concentration of prim-
ers and probes required to carry out the qPCR reaction. 
The contents of the 20X TaqMan® Assay Mix used in 
this analysis are described in Additional file 1: Table S1. 
QPCR reactions were performed on a 7900HT Real Time 
Fast PCR system (Applied Biosystems, USA) and the 
thermocycling conditions for the qPCR were identical to 
the TaqMan® SNP genotyping reaction explained in the 
previous section, except that the number of cycles was 
36.
Once the qPCR reactions were completed, the ampli-
fication data was processed using the RQ Manager 
software (Applied Biosystems, USA). The baseline cor-
rections were set manually for the FASLG and the ND-2 
amplifications separately and the amplification thresholds 
were either automatically or manually set based on the 
Applied Biosystems’ recommendations. For each qPCR 
reaction, the cycle number that bisects the threshold 
line (CT) was then exported and organized in Microsoft 
Excel© spread sheets.
For quality control measures, standard deviation (SD) 
among the CT values of triplicate amplification of each 
DNA sample was computed using a Microsoft© Excel 
function. If the SD was >0.3 for the triplicates of a DNA 
sample, then the SD was reanalyzed by excluding one 
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outlier CT value. QPCR reactions were repeated for DNA 
samples that still had a CT SD >0.3 after this step. Once 
all amplifications were completed, the average CT value 
was calculated for each DNA sample and the mtDNA 
copy number ratio in tumor tissues with respect to non-
tumor tissues was computed for each patient using the 
∆∆CT method [21]. Out of 276 patients included in this 
study, the mtDNA copy number ratio was obtained for 
274 patients. For the primary analysis, if for a patient the 
ratio of mtDNA copy number in the tumor tissue to non-
tumor tissue (mtDNAT/N) was >1, then we assumed an 
increase in mtDNA copy number in tumor tissue when 
compared to non-tumor tissue. If mtDNAT/N was <1, 
then we assumed a decrease in mtDNA copy number in 
the tumor tissue when compared to non-tumor tissue. 
For the secondary and exploratory analysis, we consid-
ered the mtDNAT/N <0.8 as a decrease and mtDNAT/N 
>1.2 as an increase in a more stringent categorization of 
the relative mtDNA copy number. During this study, the 
mtDNA ratio values were rounded off to three decimal 
digits.
Statistical analyses
Patient genotypes and the clinicopathological variables 
were coded in Microsoft® Excel spread sheets prior to 
the statistical analysis. For six mtDNA polymorphisms, 
patients with the minor allele homoplasmy and major 
allele homoplasmy were categorized in two separate 
groups. Two patients, who were detected as heteroplas-
mic (i.e. containing the both alleles) in the case of 10398 
(A/G) or 16189 (T/C) polymorphisms, were excluded 
from statistical analyses. For the mtDNA copy number 
analysis, patients with an increase in the mtDNA copy 
number in the tumor tissue relative to the non-tumor tis-
sue were categorized together and were compared with 
patients with a decrease in the mtDNA copy number 
ratio. Clinicopathological features were also categorized, 
except age, which was analyzed as a continuous variable. 
Differences among the baseline characteristics of the 
patient cohorts were tested using the Chi square test for 
the categorical variables and the Mann–Whitney U test 
for the continuous variables. The possible associations 
between the SNP genotypes or mtDNA copy number 
change and the clinicopathological variables were tested 
by Chi square or Fisher’s exact test.
There were two measures of outcome used in the sta-
tistical analysis—overall survival (OS) and disease free 
survival (DFS). For OS, death was the clinical endpoint 
and for DFS occurrence of recurrence, metastasis or 
death was the clinical endpoint. In statistical analysis, 
Cox regression method was used to estimate the hazard 
ratios (HRs) and 95% confidence intervals (CIs) together 
with p values. After the initial univariate analysis, genetic 
markers were also investigated in the multivariable 
analyses adjusting for clinicopathological factors; clin-
icopathological features with significant p values (<0.05) 
in the univariate analyses were entered in the multi-
variable models containing the genetic variables. Since 
vascular and lymphatic invasion data were highly corre-
lated (~97% of the patients had the same status for both 
invasions), we entered only the vascular invasion in the 
multivariable models. Patients who did not experience 
the outcome of interest were censored at the time of 
last follow-up. Statistical significance threshold was set 
at p =  0.05 and all tests were double-sided. All statisti-
cal analyses were done using the SPSS statistical software 
(IBM version 19, USA), unless stated otherwise.
Results
Description of the patient cohorts
In this study, two sub-cohorts of the NFCCR patient 
cohort were investigated: (1) 536 patients investigated 
for the six mtDNA polymorphisms, and (2) 276 patients 
investigated for the mtDNA copy number change. The 
baseline characteristics of these sub-cohorts are shown 
in Table 1. The median OS and DFS times were 6.3 and 
5.98 years in the 536 patient cohort and 6.2 and 5.1 years 
in the 276 patient cohort (Table  1). There were no sig-
nificant differences between the NFCCR cohort and the 
sub-cohort investigated for the relative mtDNA copy 
number in terms of their baseline characteristics (data 
not shown). However, when compared to the NFCCR 
cohort, the sub-cohort analyzed for polymorphisms had 
less stage IV patients (p < 0.001), less patients with vascu-
lar invasion (p = 0.014), and, less patients with lymphatic 
invasion (p = 0.037).
Survival analysis for the six mtDNA polymorphisms
The genotype frequencies of the six mtDNA polymor-
phisms are shown in Additional file 1: Table S1.
In the univariate analysis, none of the six mtDNA poly-
morphisms were associated with OS or DFS (Table 2). As 
expected, male sex, increasing stage, tumors with vascu-
lar and lymphatic invasions and MSI-L/MSS tumor phe-
notype were significantly associated with increased risk 
of death in the OS analysis (Additional file 2: Table S2). 
Similarly, in the univariate analysis for DFS, patients with 
tumors in rectum, male sex, tumors with advanced stage, 
vascular and lymphatic invasions and MSI-L/MSS phe-
notype were associated with increased risk of recurrence, 
metastasis or death (Additional file  2: Table S2). Multi-
variable analyses did not identify associations of these 
polymorphisms with either OS or DFS, either (Additional 
file  3: Table S3). None of the polymorphism genotypes 
were associated with the clinicopathological characteris-
tics, though for the 10398 (A/G) polymorphism and the 
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MSI status a borderline p value (p = 0.05) was detected 
(Additional file 4: Table S4).
Survival analysis for the mtDNA copy number ratio
Results of the mtDNA copy number analysis obtained in 
274 of 276 colorectal cancer patients are summarized in 
Figure  1. In this patient cohort, the ratio of mtDNA in 
tumor to non-tumor tissue (mtDNAT/N) varied between 
0.003 and 11. The majority (94.8%) of the mtDNAT/N 
were less than 3. In rare cases, a considerable increase in 
tumor mtDNA was observed (patients with mtDNAT/N 
ratios ≥3–11, n = 14). An inspection of the clinicopatho-
logical features of these 14 patients showed a tendency 
towards having tumors with stage III and IV (10 out of 
14), with MSS/MSI-L (13 out of 14) and with no BRAF1-
Val600Glu mutation (13 out of 14; the remaining patient’s 
BRAF1 mutation status was not determined).
Overall, in 108 patients (39.4%) an increase (mtDNAT/N 
>1) and in 166 patients (60.6%) a decrease (mtDNAT/N 
<1) of the mtDNA copy number was detected in tumors 
with respect to unaffected tissues (Figure 1).
The univariate analysis results for OS and DFS using 
the mtDNA copy number ratio are summarized in 
Table 3. As a result, no association of the mtDNA copy 
number change with patient outcome was detected. 
Multivariable analysis did not change these results 
(Additional file 3: Table S3). In addition, we checked the 
association of the mtDNA copy number change with the 
baseline characteristics of the patients; although there 
was a trend for association with stage (p  =  0.075) and 
microsatellite instability status (p  =  0.074), no statisti-
cally significant association was detected between the 
mtDNA copy number ratio and the patient baseline char-
acteristics shown in Table 1 (Additional file 4: Table S4). 
The statistical analysis results for the clinicopathological 
features with OS and DFS in this sub-cohort are provided 
in Additional file 5: Table S5.
As an exploratory analysis, mtDNAT/N was re-cat-
egorized into two groups following a more stringent 
definition criterion: patients with the mtDNAT/N <0.8 
(n = 131) were categorized as the patients with reduced 
mtDNA copy number and the patients with mtDNAT/N 
>1.2 (n  =  82) were categorized as the patients with 
increased mtDNA copy number. Similar to our previous 
result, in this analysis as well there was no evidence of 
association of the mtDNA copy number change with OS 
or DFS in colorectal cancer (Additional file 6: Table S6).
Discussion
Identifying biomarkers that can predict the outcome in 
cancer patients is a hot topic in cancer research. Mito-
chondrial dysfunction has been linked to the initiation 
and progression of cancers [22–24]. Thus, mitochon-
drial DNA variations are biologically relevant, potential 
prognostic markers in cancer. In this study we have ana-
lyzed the associations of overall and disease-free survival 
times with the genotypes of six mtDNA polymorphisms 
[MitoT479C, MitoT491C, MitoT10035C, MitoA13781G, 
16189 (T/C) and 10398 (A/G)] in 536 patients and the 
mtDNA copy number ratio in tumor tissues to non-
tumor tissues in 274 patients. Our results suggest that 
none of these mtDNA variations are linked to prognostic 
characteristics of colorectal cancer patients.
MtDNA polymorphisms and their relation to prognosis 
in colorectal cancer
The mtDNA D-loop region contains the initiation sites 
for the mtDNA replication and transcription, thus vari-
ations in this region may influence these important 
mitochondrial processes. We studied three polymor-
phisms located in the D-loop: MitoT491C, MitoT479C 
and mtDNA 16189 (T/C). There is no report in litera-
ture studying the biological effects of the MitoT491C 
and the MitoT479C polymorphisms, but the 16189 
Table 2 Univariate analysis results for the six mtDNA polymorphisms investigated
Reference categories are italicized.
CI confidence interval, HR hazard ratio, n number of patients, vs versus.
Variables n p value HR 95% CI Variables n p value HR 95% CI
Lower Upper Lower Upper
Overall survival Disease free survival
 MitoT479C (C vs T) 529 0.451 0.731 0.323 1.652  MitoT479C (C vs T) 528 0.917 0.965 0.495 1.884
 MitoT491C (C vs T) 503 0.631 1.169 0.617 2.215  MitoT491C (C vs T) 502 0.182 1.466 0.835 2.574
 MitoT10035C (C vs T) 534 0.916 0.968 0.526 1.781  MitoT10035C (C vs T) 533 0.970 1.011 0.577 1.772
 MitoA13781G (G vs A) 522 0.734 0.895 0.473 1.695  MitoA13781G (G vs A) 521 0.834 0.940 0.524 1.684
 10398 (G vs A) 528 0.596 0.895 0.594 1.349  10398 (G vs A) 527 0.946 1.013 0.698 1.470
 16189 (C vs T) 528 0.794 0.940 0.590 1.497  16189 (C vs T) 527 0.535 0.872 0.565 1.345
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(T/C) polymorphism has been studied by several groups. 
Briefly, the mtDNA 16189 (T/C) polymorphism is located 
in a hyper-variable region in the mitochondrial D-loop. 
This substitution leads to the formation of a homopoly-
meric C-tract between positions 16189–16194, resulting 
in a mtDNA length heteroplasmy [7]. This heteroplasmic 
length variation has been suggested to affect the mtDNA 
replication [8]. In addition, this polymorphism has been 
associated with increased oxidative damage [25]. These 
findings suggest a role for the 16189 T > C polymorphism 
in increased rate of somatic mutations in mtDNA and 
altered mitochondrial function, which makes it a good 
candidate as a prognostic marker in cancer. However, in 
this study association of this polymorphism with clinical 
outcome in colorectal cancer was not detected.
Two other polymorphisms investigated in this study 
are located in the genes coding for the OXPHOS 
proteins: the 10398 (A/G) is a non-synonymous sub-
stitution (Thr114Ala) located in the ND-3 gene and the 
MitoA13781G is a non-synonymous substitution (Ile-
482Val) located in the ND-5 gene [26, 27]. Of these two 
polymorphisms, the biological consequence of 10398 
(A/G) has been reported in literature. Kulawiec et  al. 
showed that the cybrid cell lines that had mtDNAs with 
the A-allele of this polymorphism had elevated levels of 
reactive oxygen species [6]. Also, these cybrid cell lines 
showed increased colony forming ability and promoted 
metastases in mice. Therefore, the 10398 (A/G) polymor-
phism has several carcinogenesis and progression related 
effects, yet our results do not support a role of this poly-
morphism in progression of colorectal cancer.
Similar to other polymorphisms investigated in 
this study, we did not identify an association of the 
MitoT10035C polymorphism with overall and disease 
Figure 1 The mtDNA ratio in tumor tissue versus non-tumor tissues in the patients.
Table 3 Univariate analysis results for the mtDNA copy number change in tumor tissues with respect to non-tumor tis-
sues
Reference categories are italicized.
CI confidence interval, HR hazard ratio, n number of patients, vs versus.
Variable n p value HR 95% CI Variable n p value HR 95% CI
Lower Upper Lower Upper
Overall survival Disease free survival
 mtDNA copy number 
(increase vs decrease)
273 0.389 1.163 0.825 1.640  mtDNA copy number 
(increase vs decrease)
272 0.389 1.154 0.833 1.601
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free survivals in colorectal cancer patients. This poly-
morphism is located in a mitochondrial tRNA gene and 
whether or not it causes an alteration in mitochondrial 
function is currently unknown.
In contrast to polymorphisms from the nuclear DNA 
genes, mtDNA polymorphisms and their associa-
tions with prognosis in colorectal cancer patients have 
been rarely studied [28, 29]. In one of these studies, the 
MitoT479C, MitoT491C, MitoT10035C, MitoA13781G 
and 10398 (A/G) polymorphisms were not found to be 
associated with outcome in a large Scottish colorectal 
cancer cohort [29]. Hence, the results that we obtained 
in our study are concordant with these published results. 
Yet to our knowledge, this is the first time that the asso-
ciation of the 16189 (T/C) polymorphism with outcome 
was investigated in colorectal cancer.
MtDNA copy number change and its relation to prognosis 
in colorectal cancer
The number of mitochondria may increase or decrease 
in normal tissues based on the energy requirements of 
the cells. In cancer, the altered energy needs of the tumor 
cells and the somatic mutations in mtDNA are likely to 
contribute to changes in the copy number of mitochon-
dria (thus, the copy number of mtDNA) [9, 13, 23]. In 
fact, differences in copies of mtDNA in tumor tissues 
when compared to surrounding unaffected tissues have 
been shown in various cancers, such as ovarian [30], 
breast [31], and colorectal cancers [9–13, 32].
In colorectal cancer, associations of the mtDNA copy 
number change with clinicopathological features, notably 
stage and outcome, were also reported [10–12, 32]. While 
the differences in experimental approaches and the cut-
off value used to define the relative mtDNA copy number 
make an objective comparison of these studies difficult, 
they are nevertheless briefly discussed here. Feng et al. [12] 
showed that except one patient, the quantity of mtDNA 
was higher in tumors compared to adjacent non-tumor tis-
sues in 44 patients from China and this increase was asso-
ciated with the disease stage. In contrast, Cui et  al. [32] 
reported that the 70% of the 60 Chinese colorectal cancer 
patients had decreased mtDNA copy number in tumor tis-
sues compared to the non-tumor tissue. When they used 
a cut-off threshold of <0.72 to define a decreased mtDNA 
copy number, these authors did find an association of 
mtDNA copy number with the lymph-node metastasis in 
the univariate analyses, but not with 3-year overall survival 
and the clinicopathological features including the stage. 
Lin and co-authors, on the other hand, reported a two-fold 
increase of mtDNA copy number in tumors of 39% of 153 
colorectal cancer patients from Taiwan [10]. These authors 
also found that the decrease in mtDNA content in tumor 
tissue when compared to normal tissue was associated 
with shorter 5-year overall survival (and advanced stage) 
in the univariate but not in multivariable analysis. In the 
same study, an association with 5-year disease-free sur-
vival was not detected [10]. Presumably the same group in 
another study reported the mtDNA copy number change 
in 194 colorectal cancer patients also from Taiwan [11]. 
In this study, the mtDNA copy numbers were considered 
to be decreased if the estimated mtDNA quantity in the 
tumor tissue was less than 2/3 of the mtDNA quantity 
in the unaffected tissue. This study showed a decreased 
tumor mtDNA copy number in 28% of the patients and 
associations of the decreased mtDNA copy number with 
stage and reduced 5-year disease-free survival in univari-
ate analysis, but not in multivariable analysis [11].
In our analysis, we observed an increase or decrease 
of the mtDNA copy number in tumor tissues of ~39 and 
~61% of the patients, respectively (Figure 1), however we 
did not find any association between the mtDNA copy 
number change status and overall and disease-free sur-
vivals in our cohort (Table 3; Additional file 3: Table S3). 
Using a stringent threshold to define the increase and 
decrease in relative mtDNA copy number did not change 
these results (Additional file 6: Table S6). We also did not 
identify statistically significant associations between the 
baseline characteristics, including stage, and the mtDNA 
copy number change status in our patient cohort (Addi-
tional file  4: Table S4). Our results therefore contradict 
the previously published results showing the association 
of the mtDNA copy number ratio with clinicopatho-
logical or outcome characteristics in colorectal cancer 
patients [10–12, 32]. This discrepancy in results can be 
attributed to the differences between these studies and 
ours (such as analyzing cohorts with different follow-
up periods, ethnicities, baseline clinicopathological or 
tumor molecular characteristics) in addition to the dif-
ferences in study designs (such as the application of dif-
ferent cut-off values to define the increase or decrease of 
the relative mtDNA copy number). Clearly, based on ours 
and previously published results, a consistent conclusion 
on the degree of the change of the mtDNA copy number 
in colorectal tumors and its association with patient clin-
icopathological features and clinical outcome cannot be 
made. Further studies are needed to elucidate whether or 
not the tumor mtDNA copy number change is a prognos-
tic marker in colorectal cancer.
A limitation of our study was that the NFCCR patient 
sub-cohort genotyped for the polymorphisms was biased 
towards earlier stages when compared to the entire 
NFCCR patient cohort. This bias should be kept in mind 
while interpreting our results. On the other hand, it is 
also one of the few fairly large colorectal cancer cohorts 
investigated for prognostic associations of mtDNA poly-
morphisms. In addition, to our knowledge this is the first 
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study that investigated the mtDNA 16189 (T/C) poly-
morphism and survival characteristics of the colorectal 
cancer patients. This is also the first time the mtDNA 
copy number change was investigated in relation to clini-
cal outcome in Caucasian colorectal cancer patients. 
While this NFCCR patient sub-cohort is characterized 
by a relatively long-follow up period and is also unique 
in being the largest cohort studied till date (n = 274), we 
cannot rule out the possibility that our sample size may 
not be large enough to detect a possible association of the 
mtDNA copy number change with outcome.
Conclusions
Overall, comprehensive studies on large patient cohorts 
are required to identify the potential prognostic roles of 
the mtDNA variations investigated in this study and the 
survival outcomes of colorectal cancer patients.
Abbreviations
CI: confidence interval; CT: the cycle number that bisects the threshold line; 
DFS: disease-free survival; HR: hazards ratio; HREB: human research ethics 
board; MAF: minor allele frequency; MSI: microsatellite instability; MSI-H: 
microsatellite instability-high; MSI-L: microsatellite instability-low; MSS: micro-
satellite stable; mtDNA: mitochondrial DNA; mtDNAT/N: the ratio of mtDNA 
copy number in the tumor tissue to non-tumor tissue; ND3: NADH dehydro-
genase 3; ND5: NADH dehydrogenase 5; NFCCR: Newfoundland colorectal 
cancer registry; OS: overall survival; OXPHOS: oxidative phosphorylation 
pathway; SDS: sequence detection system; vs: versus; qPCR: quantitative 
polymerase chain reaction.
Authors’ contribution
AMSHM performed the TaqMan genotyping and qPCR experiments and 
statistical analyses, and drafted the manuscript. ED contributed substantially 
to the collection of clinical and prognostic data for the patient cohorts. PP 
provided the patient clinical and prognostic data, provided the genotype data 
for four polymorphisms, and contributed to the design of the study. RG pro-
vided the DNA samples of patients extracted from the blood and tissue blocks 
and contributed to the design of the study. SS conceived the idea, designed 
and led the project, helped draft the manuscript, finalized and submitted the 
manuscript. All authors read and approved the final manuscript.
Additional files
Additional file 1: Table S1. Details of the TaqMan® SNP genotyping and 
qPCR reactions and the genotype frequencies of the mtDNA polymor-
phisms investigated.
Additional file 2: Table S2. Results of the univariate analyses for the 
clinicopathological features (SNP genotyped cohort).
Additional file 3: Table S3. Multivariable analysis results for the six 
mtDNA SNPs and the mtDNA copy number change.
Additional file 4: Table S4. Chi square or Fisher exact test results for the 
mtDNA polymorphisms and copy number ratio and the clinicopathologi-
cal features.
Additional file 5: Table S5. Results of the univariate analyses for the 
clinicopathological features (qPCR cohort).
Additional file 6: Table S6. Univariate analysis for the secondary 
mtDNA copy number ratio classification.
Author details
1 Discipline of Genetics, Faculty of Medicine, Memorial University of New-
foundland, 300 Prince Philip Drive, HSC, Room H4333, St. John’s, NL A1B 3V6, 
Canada. 2 Clinical Epidemiology Unit, Faculty of Medicine, Memorial University 
of Newfoundland, St. John’s, NL, Canada. 3 Discipline of Oncology, Faculty 
of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada. 
Acknowledgements
We express our sincere gratitude to the patients recruited to the NFCCR, 
Ms. Michelle Simms for technical assistance with DNA samples, Ms. Andrea 
Kavanagh for retrieval of the prognostic data from the NFCCR database, 
and other NFCCR investigators and personnel for their contributions to the 
NFCCR. This study is supported by the Medical Research Foundation-Cox 
Award (2010)-Memorial University of Newfoundland, the Canadian Institutes 
of Health Research (CIHR) and the Atlantic Innovation Fund (Atlantic Canada 
Opportunities Agency). The funding sources had no involvement in the study 
design; in the collection, analysis or interpretation of data; in the writing of the 
report; or in the decision to submit the paper for publication.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 23 March 2015   Accepted: 17 June 2015
References
 1. Boyle P, Langman JS (2000) ABC of colorectal cancer: epidemiology. BMJ 
321(7264):805–808
 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates 
of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 
127(12):2893–2917
 3. Wallace DC (2005) A mitochondrial paradigm of metabolic and degen-
erative diseases, aging, and cancer: a dawn for evolutionary medicine. 
Annu Rev Genet 39:359–407
 4. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J 
et al (1981) Sequence and organization of the human mitochondrial 
genome. Nature 290(5806):457–465
 5. Lee HC, Chang CM, Chi CW (2010) Somatic mutations of mitochon-
drial DNA in aging and cancer progression. Ageing Res Rev 9(Suppl 
1):S47–S58
 6. Kulawiec M, Owens KM, Singh KK (2009) mtDNA G10398A variant in 
African–American women with breast cancer provides resistance to 
apoptosis and promotes metastasis in mice. J Hum Genet 54(11):647–654
 7. Bendall KE, Sykes BC (1995) Length heteroplasmy in the first hypervari-
able segment of the human mtDNA control region. Am J Hum Genet 
57(2):248–256
 8. Liou CW, Lin TK, Chen JB, Tiao MM, Weng SW, Chen SD et al (2010) 
Association between a common mitochondrial DNA D-loop polycytosine 
variant and alteration of mitochondrial copy number in human periph-
eral blood cells. J Med Genet 47(11):723–728
 9. Chen T, He J, Shen L, Fang H, Nie H, Jin T (2011) The mitochondrial DNA 
4,977-bp deletion and its implication in copy number alteration in colo-
rectal cancer. BMC Med Genet 12:8
 10. Lin PC, Lin JK, Yang SH, Wang HS, Li AF, Chang SC (2008) Expression of 
beta-F1-ATPase and mitochondrial transcription factor A and the change 
in mitochondrial DNA content in colorectal cancer: clinical data analysis 
and evidence from an in vitro study. Int J Color Dis 23(12):1223–1232
 11. Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK (2009) Mitochon-
drial D-loop mutation is a common event in colorectal cancers with p53 
mutations. Int J Color Dis 24(6):623–628
 12. Feng S, Xiong L, Ji Z, Cheng W, Yang H (2011) Correlation between 
increased copy number of mitochondrial DNA and clinicopathological 
stage in colorectal cancer. Oncol Lett 2(5):899–903
Page 10 of 10Haja Mohideen et al. BMC Res Notes  (2015) 8:272 
 13. Lee HC, Yin PH, Lin JC, Wu CC, Chen CY, Wu CW et al (2005) Mitochondrial 
genome instability and mtDNA depletion in human cancers. Ann N Y 
Acad Sci 1042:109–122
 14. Woods MO, Younghusband HB, Parfrey PS, Gallinger S, McLaughlin J, 
Dicks E et al (2010) The genetic basis of colorectal cancer in a popu-
lation-based incident cohort with a high rate of familial disease. Gut 
59(10):1369–1377
 15. Green RC, Green JS, Buehler SK, Robb JD, Daftary D, Gallinger S et al 
(2007) Very high incidence of familial colorectal cancer in Newfoundland: 
a comparison with Ontario and 13 other population-based studies. Fam 
Cancer 6(1):53–62
 16. Negandhi AA, Hyde A, Dicks E, Pollett W, Younghusband BH, Parfrey P 
et al (2013) MTHFR Glu429Ala and ERCC5 His46His polymorphisms are 
associated with prognosis in colorectal cancer patients: analysis of two 
independent cohorts from Newfoundland. PLoS One 8(4):e61469
 17. Juo SH, Lu MY, Bai RK, Liao YC, Trieu RB, Yu ML et al (2010) A common 
mitochondrial polymorphism 10398A > G is associated metabolic syn-
drome in a Chinese population. Mitochondrion 10(3):294–299
 18. The dbSNP database. (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
Accessed 22 June 2015
 19. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al 
(2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 
29(1):308–311
 20. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C et al (2003) 
Increased mitochondrial DNA content in peripheral blood lymphocytes 
from HIV-infected patients with lipodystrophy. Antivir Ther 8(4):315–321
 21. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. 
Methods 25(4):402–408
 22. Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM et al (2006) Proteomic analysis 
of colorectal cancer reveals alterations in metabolic pathways: mecha-
nism of tumorigenesis. Mol Cell Proteomics 5(6):1119–1130
 23. Lee HC, Wei YH (2009) Mitochondrial DNA instability and metabolic shift 
in human cancers. Int J Mol Sci 10(2):674–701
 24. Ishikawa K, Hayashi J (2010) A novel function of mtDNA: its involvement 
in metastasis. Ann N Y Acad Sci 1201:40–43
 25. Lin TK, Chen SD, Wang PW, Wei YH, Lee CF, Chen TL et al (2005) Increased 
oxidative damage with altered antioxidative status in type 2 diabetic 
patients harboring the 16189 T to C variant of mitochondrial DNA. Ann N 
Y Acad Sci 1042:64–69
 26. The mtdb database. (http://www.mtdb.igp.uu.se/). Accessed 22 June 
2015
 27. Ingman M, Gyllensten U (2006) mtDB: human mitochondrial genome 
database, a resource for population genetics and medical sciences. 
Nucleic Acids Res 34(Database issue):D749–D751
 28. Lascorz J, Bevier M, Schonfels WV, Kalthoff H, Aselmann H, Beckmann J 
et al (2012) Polymorphisms in the mitochondrial oxidative phosphoryla-
tion chain genes as prognostic markers for colorectal cancer. BMC Med 
Genet 13:31
 29. Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, Porte-
ous ME et al (2010) Association between common mtDNA variants and 
all-cause or colorectal cancer mortality. Carcinogenesis 31(2):296–301
 30. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY (2006) Association of 
decreased mitochondrial DNA content with ovarian cancer progression. 
Br J Cancer 95(8):1087–1091
 31. Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei X et al (2007) Reduced mito-
chondrial DNA copy number is correlated with tumor progression and 
prognosis in Chinese breast cancer patients. IUBMB Life 59(7):450–457
 32. Cui H, Huang P, Wang Z, Zhang Y, Zhang Z, Xu W et al (2013) Associa-
tion of decreased mitochondrial DNA content with the progression of 
colorectal cancer. BMC Cancer 13:110
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
